Epstein-Barr Virus load in children infected with Human Immunodeficiency Virus type 1 in Uganda

Journal of Infectious Diseases

Volumn 210, Issue 3, 2014, Pages 392-399

  Petrara, Maria Raffaella ^a,b   Penazzato, Martina ^c,g   Massavon, William ^g   Nabachwa, Sandra ^h   Nannyonga, Maria ^h   Mazza, Antonio ^f,g   Gianesin, Ketty ^a,b   Del Bianco, Paola ^d   Lundin, Rebecca ^e   Sumpter, Colin ⁱ   Zanchetta, Marisa ^d   Giaquinto, Carlo ^c,g   De Rossi, Anita ^a,b,d  

^a Departments of Molecular Immunology and Oncology   (Italy)

^b Department of Oncology and Surgical Sciences   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^e Intl Maternal Pediatric Adolescent AIDS Clinical Trials   (Italy)

^f Hospital of Cles   (Italy)

^g Tukula Fenna Project   (Uganda)

^h St Francis Hospital Uganda   (Uganda)

ⁱ LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

African children; Antiretroviral therapy; EBV; HIV 1; Immune activation

Indexed keywords

DNA 16S; VIRUS DNA; VIRUS RNA; EFAVIRENZ; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; CHILD; CHILD HEALTH; DISEASE ASSOCIATION; DNA DETERMINATION; DRIED BLOOD SPOT TESTING; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS TYPE 1; EPSTEIN BARR VIRUS TYPE 2; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; NEWBORN; NONHUMAN; NUCLEIC ACID ANALYSIS; PRIORITY JOURNAL; TREATMENT DURATION; UGANDA; VIRUS DETECTION; VIRUS LOAD; VIRUS REPLICATION; CD4 LYMPHOCYTE COUNT; EPSTEIN BARR VIRUS INFECTION; HUMAN CELL; IMMUNOSTIMULATION; INFANT; MIXED INFECTION; QUANTITATIVE ANALYSIS; SCHOOL CHILD; TREATMENT OUTCOME; VIRUS TRANSMISSION;

AFRICAN CHILDREN; ANTIRETROVIRAL THERAPY; EBV; HIV-1; IMMUNE ACTIVATION;

ADOLESCENT; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HIV INFECTIONS; HIV-1; HUMANS; INFANT; MALE; VIRAL LOAD;

EID: 84904356168     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu099     Document Type: Article

References (42)

1. Beral V, Newton R. Overview of the epidemiology of immunodeficiencyassociated cancers. J Natl Cancer Inst Monogr 1998; 23:1-6.
2. Carbone A, Cesarman E, Spina M, Gloghini A, Schulz TF. HIV-associated lymphomas and gamma-herpesviruses. Blood 2009; 113:1213-24.
3. Douek DC, Roederer M, Koup RA. Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med 2009; 60:471-84.
4. Grulich AE, Wan X, Law MG, et al. B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS. AIDS 2002; 14:133-40.
5. Moir S, Fauci AS. B-cells in HIV infection and disease. Nat Rev Immunol 2009; 9:235-45.
6. Gaidano G, Dalla-Favera R. Molecular pathogenesis of AIDS-related lymphomas. Adv Cancer Res 1995; 67:113-53.
7. Ometto L, Menin C, Masiero S, et al. Molecular profile of Epstein-Barr virus in human immunodeficiency virus type 1-related lymphadenopathies and lymphomas. Blood 1997; 90:313-22.
8. Righetti E, Ballon G, Ometto L, et al. Dynamics of Epstein-Barr virus in HIV-1 infected subjects on highly active antiretroviral therapy. AIDS 2002; 16:63-73.
9. Burighel N, Ghezzi S, Nozza S, et al. Differential dynamics of Epstein-Barr virus in individuals infected with human immunodeficiency virus-1 receiving intermittent interleukin-2 and antiretroviral therapy. Haematologica 2006; 91:244-7.
10. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-71.
11. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
12. Simard EP, Pfeiffer RM, Engels EA. Cumulative incidence of cancer among individuals with Acquired Immunodeficiency Syndrome in the United States. Cancer 2011; 117:1089-96.
13. Rickinson AB, Kieff E. Epstein-Barr virus. In: Knipe DM, Howley PM, eds. Fields virology, 5th ed. Philadelphia: Lippincott Williams and Wilkins, 2007:2656-88.
14. Walusansa V, Okuku F, Orem J. Burkitt lymphoma in Uganda, the legacy of Denis Burkitt and an update on the disease status. Br J Haematol 2012; 156:757-60.
15. Cader FZ, Kearns P, Young L, Murray P, Vockerodt M. The contribution of the Epstein-Barr virus to the pathogenesis of childhood lymphomas. Cancer Treat Rev 2010; 36:348-53.
16. Molyneux EM, Rochford R, Griffin B, et al. Burkitt's lymphoma. Lancet 2012; 379:1234-44.
17. Mueller BU. Cancers in children infected with the human immunodeficiency virus. Oncologist 1999; 4:309-17.
18. Davidson A, Hendricks M. Experience with B-cell lymphoma at a South African centre in the HIV Era. Transfus Apher Sci 2013; 49: 31-9.
19. Slyker JA, Casper C, Tapia K, et al. Clinical and virologic manifestations of primary Epstein-Barr virus (EBV) infection in Kenyan infants born to HIV-infected women. J Infect Dis 2013; 207:1798-806.
20. World Health Organization. Antiretroviral therapy of HIV infection in infants and children in resource-limited settings:towards universal access. Recommendations for a public health approach. Geneva: World Health Organization, 2006. Available at: http://www.who.int/hiv/pub/guidelines/WHOPMTCT.pdf. Accessed 9 December 2013.
21. Abbate I, Zanchetta M, Gatti M, et al. Multicenter comparative study of Epstein-Barr virus DNA quantification for virological monitoring in transplanted patients. J Clin Virol 2011; 50:224-9.
22. Petrara MR, Cattelan AM, Zanchetta M, et al. Epstein-Barr virus load and immune activation in human immunodeficiency virus type 1-infected patients. J Clin Virol 2012; 53:195-200.
23. Jiang W, Lederman MM, Hunt P, et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis 2009; 199:1177-85.
24. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: World Health Organization, 2013. Available at: www.who.int/hiv/pub/guidelines/arv2013.
25. Jamieson DJ, Clark J, Kourtis AP, et al. Recommendations for human immunodeficiency virus screening, prophylaxis, and treatment for pregnant women in the United States. Am J Obstet Gynecol 2007; 197: S26-32.
26. Rickinson AB, Young LS, Rowe M. Influence of the Epstein-Barr virus nuclear antigen EBNA2 on the growth phenotype of virus transformed B cells. J Virol 1987; 61:1310-7.
27. Buisson M, Morand P, Peoc'h M, Bouchard O, Bourgeat MJ, Seigneurin JM. Development of an Epstein-Barr virus type 2 (EBV-2)-associated hepatic B cell non-Hodgkin's lymphoma in an HIV-1-infected patient following a change in the EBV dominant type. Leukemia 1999; 13: 298-301.
28. Miller WE, Edwards RH, Walling DM, Raab-Traub N. Sequence variation in the Epstein-Barr virus latent membrane protein 1. J Gen Virol 1994; 75:2729-40.
29. Mainou BA, Raab-Traub N. LMP1 strain variants: biological and molecular properties. J Virol 2006; 80:6458-68.
30. Brambilla D, Jennings C, Aldrovandi G, et al. Multicenter evaluation of use of dried blood and plasma spot specimens in quantitative assays for human immunodeficiency virus RNA: measurement, precision, and RNA stability. J Clin Microbiol 2003; 41:1888-93.
31. Waters L, Kambugu A, Tibenderana H, et al. Evaluation of filter paper transfer of whole-blood and plasma samples for quantifying HIV RNA in subjects on antiretroviral therapy in Uganda. J Acquir Immune Defic Syndr 2007; 46:590-3.
32. Monleau M, Montavon C, Laurent C, et al. Evaluation of different RNA extraction methods and storage conditions of dried plasma or blood spots for human immunodeficiency virus type 1 RNA quantification and PCR amplification for drug resistance testing. J Clin Microbiol 2009; 47:1107-18.
33. Steinmetzer K, Seidel T, Stallmach A, Ermantraut E. HIV load testing with small samples of whole blood. J Clin Microbiol 2010; 48: 2786-92.
34. Zanchetta M,Walker S, Burighel N, et al. Long-term decay of the HIV-1 reservoir in HIV-1-infected children treated with highly active antiretroviral therapy. J Infect Dis 2006; 193:1718-27.
35. Pinzone MR, Di Rosa M, Cacopardo B, Nunnari G. HIV RNA suppression and immune restoration: can we do better? Clin Dev Immunol 2012; 2012:515962.
36. Pasternak AO, Lukashov VV, Berkhout B. Cell-associated HIV RNA: a dynamic biomarker of viral persistence. Retrovirology 2013; 10:41.
37. Anselmi A, Vendrame D, Rampon O, Giaquinto C, Zanchetta M, De Rossi A. Immune reconstitution in human immunodeficiency virus type 1-infected children with different virological responses to anti-retroviral therapy. Clin Exp Immunol 2007; 150:442-50.
38. Papasavvas E, Azzoni L, Foulkes A, et al. Increased microbial translocation in ≤180 days old perinatally human immunodeficiency virus-positive infants as compared with human immunodeficiency virus-exposed uninfected infants of similar age. Pediatr Infect Dis J 2011; 30:877-82.
39. Sandler NG, Douek DC. Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat Rev Microbiol 2012; 10:655-66.
40. Snijdewind IJ, van Kampen JJ, Fraaij PL, van der Ende ME, Osterhaus ADGruters RA. Current and future applications of dried blood spots in viral disease management. Antiviral Res 2012; 93:309-21.
41. Kabyemera R, Masalu N, Rambau P, et al. Relationship between Non-Hodgkin's lymphoma and blood levels of Epstein-Barr Virus in children in north-western Tanzania: a case control study. BMC Pediatr 2013; 13:4.
42. Parkin N, de Mendoza C, Schuurman R, et al; WHO DBS Genotyping Working Group. Evaluation of in-house genotyping assay performance using dried blood spot specimens in the Global World Health Organization laboratory network. Clin Infect Dis 2012; 54 (Suppl 4):S273-9.